We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.
- Authors
Amor, Sandra; Baker, David; Khoury, Samia J.; Schmierer, Klaus; Giovanonni, Gavin
- Abstract
A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic[1] is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of contracting SARS-CoV-2 and more severe disease. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?.
- Subjects
COVID-19; MULTIPLE sclerosis; LYMPHOPENIA; COVID-19 pandemic; AGAMMAGLOBULINEMIA; SARS virus
- Publication
Annals of Neurology, 2020, Vol 87, Issue 6, p794
- ISSN
0364-5134
- Publication type
editorial
- DOI
10.1002/ana.25770